About the API
Apixaban is an anti-clotting substance used to reduce the risk of stroke and systemic embolism (blood coagulation) in patients with nonvalvular atrial fibrillation (abnormal heart rhythm that is not caused by a heart valve problem).Atrial fibrillation (AF) occurs when the two upper chambers (atria) of the heart do not contract properly, allowing formation of blood clots, which can travel to other parts of the body. When a clot blocks blood flow to the heart or the brain, a heart attack or stroke can follow. Blood clots can wreak havoc in other parts of the body as well.
Apixaban has also been approved in other instances of blood clotting – to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of their recurrence following initial therapy. It is also indicated for the prophylaxis of DVT, which may lead to PE, in patients who have undergone hip or knee replacement surgery. DVT is a blood clot in a vein, generally in the lower leg, thigh, or pelvis, which partially or totally blocks blood flow. PE is a blood clot blocking one or more vessels in the lungs.
Apixaban is administered orally.
Apixaban was approved by the FDA in 2012, under the trade name Eliquis, to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF. In 2014, it was approved for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. It is synthesized through a multi-step chemical process.